The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

Share :
Published: 13 Dec 2012
Views: 4224
Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA

Prof Jan Burger presents data at an ASH 2012 press conference on the combination of the novel investigational agent ibrutinib with an established therapeutic antibody, rituximab, may present a safer and more effective option than the current standard chemotherapy-based treatment regimen for patients with high-risk CLL.